City

Clinical trials near Shenzhen, China

Active studies with a listed research site in Shenzhen, China.

13active studies

8recruiting now

9countries represented

138largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 3

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Obesity, OverweightCondition

NNC0487-0111, Placebo (matched to NNC0487-0111)Treatment

Australia, China92 locations

Novo Nordisk A/SSponsor

Updated 2026-08-04 · NCT07571109See eligibility →

Recruiting nowPhase 2

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

Prediabetes, Insulin ResistanceCondition

MOTS-c (MDP), PlaceboTreatment

China1 locations

Hudson BiotechSponsor

Updated 2026-04-01 · NCT07505745See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

Obesity, Overweight (Without Type 2 Diabetes) With Weight-related ComorbiditiesCondition

Tirzepatide, PlaceboTreatment

China1 locations

Hudson BiotechSponsor

Updated 2026-03-19 · NCT07481747See eligibility →

Recruiting nowPhase 2

Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight

ObesityCondition

Retatrutide (LY3437943), PlaceboTreatment

China1 locations

Hudson BiotechSponsor

Updated 2026-03-12 · NCT07467447See eligibility →

Recruiting nowNot applicable

Shenzhen Birth Cohort Study

Pregnancy Complications, Gestational DiabetesCondition

No interventionTreatment

China1 locations

Sun Yat-sen UniversitySponsor

Updated 2019-02-05 · NCT03830879See eligibility →

Recruiting nowNot applicable

Nanshan Elderly Cohort Study

Hypertension, Type 2 Diabetes MellitusCondition

Intervention not listedTreatment

China2 locations

Sun Yat-sen UniversitySponsor

Updated 2018-06-26 · NCT03569735See eligibility →

Opening soonNot applicable

Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes

Obesity Type 2 Diabetes MellitusCondition

Fecal microbiota transplantation (FMT), Semaglutide (1 Mg Dose)Treatment

China1 locations

Eighth Affiliated Hospital, Sun Yat-sen UniversitySponsor

Updated 2026-05-20 · NCT07599046See eligibility →

Active, not recruitingNot applicable

Time-Restricted Eating for Weight-Loss Maintenance

Overweight or Obese AdultsCondition

Scheduled Weight Maintenance Nutrition Education, Time-Restricted Eating (10-Hour Window)Treatment

China10 locations

Harbin Medical UniversitySponsor

Updated 2026-08-25 · NCT07163455See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Brazil, China138 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT05869903See eligibility →

Active, not recruitingPhase 2, Phase 3

The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)

Obesity and OverweightCondition

Phase IIb：Efsubaglutide Alfa 5 mg QW, Phase IIb：Efsubaglutide Alfa 10 mg QWTreatment

China41 locations

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.Sponsor

Updated 2026-01-30 · NCT06921486See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

OSA, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, Brazil66 locations

Eli Lilly and CompanySponsor

Updated 2025-09-29 · NCT06649045See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Shenzhen, China

Current studies

Related cities